New Drug Update 2024

New Drug Update 2024 is organized by University Learning Systems (ULS).

These courses were recorded April 23-24, 2024 and are valid for credit until April 24, 2027.

Description:
Experience an Exceptional New Drug Update from Patient Outcomes Expert Dr. C. Wayne Weart, PharmD, FAPhA, FASHP, BCPS.

As a health professional it is vital to keep up on the latest information from the FDA on new prescription medications and labeling changes for existing drugs.  Dr. C. Wayne Weart is an nationally known expert on new drugs and how they compare to existing medications.

University Learning Systems has been privileged to host Dr. Weart presenting his most comprehensive New Drug Update since 1979. Dr. Weart helps you to understand the decisions behind the studies that lead to the evidence in the approval process. This ten-hour, two part on demand course was recorded during Dr. Weart’s live presentation in Key West Florida, April 23-24, 2024.

Dr. Weart is a legendary leader in the movement of using patient outcomes to direct pharmacotherapy. He communicates his exceptional understanding of the drugs and the studies that the FDA uses to approve new primary care medications. He compares and contrasts the new drugs with existing medications. Because of his exceptional command of the subject matter Dr. Weart has a large and devoted following of students and fellow professionals. Year after year, professionals return to hear this legendary expert present clinical pearls that they can incorporate into their own practices.

New Drug Update Part 1 & Part 2

Recorded April 23-24, 2024. This course is course is valid until April 24, 2027 and may be taken for credit up to that time.

Learning Objectives:

1. Identify recent FDA drug communications, including but not limited to, labeling changes, warnings, new indications, new dosage forms and MedWatch alerts.

2. Discuss the new drugs with respect to their pharmacology, pharmacokinetics, approved and unapproved indications.

3. Describe their adverse effects and drug interaction that may affect patient compliance.

4. Compare efficacy, dosage and cost to existing agent

5. Discuss the patient oriented outcomes or evidence that may or may not exist for each of the new medications and when they may or may not be appropriate to recommend for selected patients.

6. Compare pharmacotherapy outcomes vs cost/benefit between newly approved agents and existing or lower cost agents.

Student Comments from April 2024 Presentation

"Fantastic presentation! So much great information. Wayne is brilliant!"

"Dr. Weart is amazing! I learned so much!

"Dr Weart is a phenomenal expert. Highly enjoyed this conference."

"Thoroughly enjoyed Wayne! What a gift that he’s still enjoys sharing his vast knowledge with all of us."

"Excellent review of important disease states, therapies, pharmacology, and pertinent studies that relate to those disease states."

"Dr. Weart gave an excellent presentation. His overview was right on point, and I can’t wait to attend another one of his presentations."